Provided by Tiger Fintech (Singapore) Pte. Ltd.

Salarius Pharmaceuticals Inc

4.56
-0.9950-17.91%
Post-market: 4.50-0.0600-1.32%19:59 EDT
Volume:1.38M
Turnover:7.22M
Market Cap:2.32M
PE:-0.07
High:4.70
Open:4.40
Low:4.23
Close:5.56
52wk High:108.00
52wk Low:4.23
Shares:509.64K
Float Shares:509.00K
Volume Ratio:1.85
T/O Rate:270.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-66.9952
EPS(LYR):-86.9214
ROE:-660.37%
ROA:-143.52%
PB:-2.80
PE(LYR):-0.05

Loading ...

Company Profile

Company Name:
Salarius Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
2
Office Location:
2450 Holcombe Blvd.,Suite X,Houston,Texas,United States
Zip Code:
77021
Fax:
- -
Introduction:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Directors

Name
Position
William K. McVicar
Chairman
Arnold C. Hanish
Director
Bruce J. McCreedy
Director
David J. Arthur
Director
Jonathan Lieber
Director
Paul Lammers
Director
Tess Burleson
Director

Shareholders

Name
Position
Mark J. Rosenblum
Acting Chief Executive Officer, Executive Vice President and Chief Financial Officer